Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Federal Trade Commission
QuintilesIMS
Chubb
Johnson and Johnson
Dow
Cerilliant
Fuji
US Department of Justice

Generated: May 24, 2018

DrugPatentWatch Database Preview

PAZEO Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Pazeo, and when can generic versions of Pazeo launch?

Pazeo is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-seven patent family members in seventeen countries.

The generic ingredient in PAZEO is olopatadine hydrochloride. There are seventeen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the olopatadine hydrochloride profile page.
Drug patent expirations by year for PAZEO
Pharmacology for PAZEO
Synonyms for PAZEO
(11-[3-DIMETHYLAMINO-PROP-(Z)-YLIDENE]-6,11-DIHYDRO-DIBENZO[B,E]OXEPIN-2-YL)-ACETIC ACID
(11Z)-11-[3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride
(z)-11-(3-(dimethyl-amino)-propylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid
(Z)-11-[3-(Dimethylamino)propylidene]-6,11-dihydro-dibenz[b,e]oxepin-2-acetic acid hydrochloride
(Z)-11-[3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride ;Olopatadine HCL
(Z)-2-(11-(3-(Dimethylamino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetic acid
(Z)-2-(11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetic acid hydrochloride
[(2Z)-2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-5-yl]acetic acid
[(2Z)-2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-5-yl]acetic acid hydrochloride
[11-(3-Dimethylamino-propylidene)-6,11-dihydro-dibenzo[b,e]oxepin-2-yl]-acetic acid; hydrochloride
{(11Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenzo[b,e]oxepin-2-yl}acetic acid
11-((z)-3-(dimethyl-amino)propylidene)-6,11-dihydrodibenz[b,e]oxepin-2-ac
11-((Z)-3-(Dimethyl-amino)propylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid
11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid
11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid hydrochloride
11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid, hydrochloride
11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid
113806-05-6
113806-05-6 (Parent)
140462-76-6
140462-76-6 (hydrochloride)
2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid
2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid hydrochloride
2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid;hydrochloride
2-[(2Z)-2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0;{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-5-yl]acetic acid
2XG66W44KF
806O056
AB00698500_11
AB00698500-07
AB00698500-09
AB00698500-10
AB0107085
AB2000599
AC1NQXZH
AC1NR00D
AK163558
AK468878
AKOS005557129
AKOS015895232
AKOS025149118
AKOS025149450
AKOS026750048
AL-4943A
Allelock
Allelock (TN)
ALO 4943A
ALO-4943A
ALO4943A
AM84372
AN-33374
API0005265
BCP9001022
BDBM50002096
BIDD:GT0285
Bio-0072
BRD-K37130586-003-01-3
C-21208
C07789
CAS-140462-76-6
CCG-101141
CHEBI:31933
CHEBI:94593
CHEMBL1189432
CHEMBL1719
CPD000469220
CS-2532
D01192
D05GPO
D08293
D27V6190PM
DB00768
DE 114
Dibenz(b,e)oxepin-2-acetic acid, 11-(3-(dimethylamino)propylidene)-6,11-dihydro-, hydrochloride, (Z)-
Dibenz(b,e)oxepin-2-acetic acid, 11-(3-dimethylamino)propylidene)-6,11-dihydro-, hydrochloride, (Z)-
Dibenz[b,e]oxepin-2-acetic acid, 11-[3-(dimethylamino)propylidene]-6,11-dihydro-, hydrochloride (1:1), (11Z)-
DR002080
DSSTox_CID_26486
DSSTox_GSID_46486
DSSTox_RID_81657
DTXSID0046486
DTXSID3023390
EX-A1347
FT-0082377
GTPL7249
H06O056
HCl of KW 4679
HMS2089K10
HVRLZEKDTUEKQH-NOILCQHBSA-N
HY-B0426A
HYDROGEN PATANOL CHLORIDE
JBIMVDZLSHOPLA-LSCVHKIXSA-N
KS-1228
KW 4679
KW-4679
KW-4943A
KW4679
L000748
LS-172239
LS-61598
MFCD00875716
MLS001401465
MLS006011811
MolPort-003-986-254
MolPort-003-986-408
NC00391
NCGC00164623-01
NCGC00263532-01
O-PPDS
O0361
Olopatadin
Olopatadina
Olopatadine
Olopatadine (hydrochloride)
Olopatadine (INN)
Olopatadine [INN:BAN]
OLOPATADINE BASE
OLOPATADINE HCl
Olopatadine Hydrochlorde
OLOPATADINE HYDROCHLORIDE
Olopatadine hydrochloride (JP17/USAN)
Olopatadine hydrochloride (Opatanol)
Olopatadine hydrochloride [USAN:USP]
Olopatadine hydrochloride tablets (JP17)
Olopatadine hydrochloride, >=98% (HPLC)
Olopatadine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Olopatadinum
Olopax
Olopine
Opatanol
Opatanol (TN)
Opatanol;Pataday;Patanase;Allelock
Pataday
Pataday (TN)
Patadine
Patanase
Patanase (TN)
Patanol
Patanol (TN)
Patanol S (TN)
PB17188
PubChem18816
Q-201511
s2494
SAM001246802
SBB066095
SCHEMBL23213
SCHEMBL4668
SMR000469220
SMR004703490
STK624184
TL8000403
TL8000904
Tox21_112242
Tox21_112242_1
UNII-2XG66W44KF
UNII-D27V6190PM
ZINC1850

US Patents and Regulatory Information for PAZEO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp PAZEO olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 206276-001 Jan 30, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Novartis Pharms Corp PAZEO olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 206276-001 Jan 30, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Novartis Pharms Corp PAZEO olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 206276-001 Jan 30, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Novartis Pharms Corp PAZEO olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 206276-001 Jan 30, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for PAZEO
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Ophthalmic Solution 0.7% ➤ Subscribe 2015-09-10

or, see our see our flat-rate plans

Supplementary Protection Certificates for PAZEO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0040 France ➤ Sign Up PRODUCT NAME: OLOPATADINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/02/217/001 20020517
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Merck
Healthtrust
Medtronic
Boehringer Ingelheim
Johnson and Johnson
Moodys
Deloitte
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.